Patents by Inventor Yayoi Wada

Yayoi Wada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE
    Publication number: 20240066047
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 29, 2024
    Inventors: MASATO YOSHIKAWA, MORIHISA SAITOH, TAISUKE KATO, YAYOI NAKAYAMA, TOMOHIRO SEKI, YASUO NAKAGAWA, YUSUKE TOMINARI, MASAKI SETO, YUSUKE SASAKI, MASANORI OKANIWA, TSUNEO ODA, AKITO SHIBUYA, KOSUKE HIDAKA, ZENYU SHIOKAWA, SHUMPEI MURATA, ATSUTOSHI OKABE, YOSHIHISA NAKADA, MICHIYO MOCHIZUKI, BRIAN SCOTT FREEZE, TAISUKE TAWARAISHI, YASUFUMI WADA, PAUL D. GREENSPAN
  • Method for expressing polypeptide having anti-tumor activity
    Patent number: 5151349
    Abstract: Disclosed is a human TNF derivative with a reduced tendency to cause adverse side effects that is obtained by replacing the 31st and 32nd arginine residues from the N-terminal of the amino acid sequence of human TNF, which has a potential for causing serious adverse effects, with asparagine residue and threoine residue, respectively, as well as a method of preparing the same utilizing recombinant DNA technology.
    Type: Grant
    Filed: January 31, 1990
    Date of Patent: September 29, 1992
    Assignee: Suntory Limited
    Inventors: Shoji Tanaka, Masafumi Tsujimoto, Yayoi Wada, Nobuo Tsuruoka, Hiroshi Nakazato
  • Novel polypeptide having an anti-tumor activity and a method of preparation thereof
    Patent number: 4948875
    Abstract: Disclosed is a human TNF derivative with a reduced tendency to cause adverse side effects that is obtained by replacing the 31st and 32nd arginine residues from the N-terminal of the amino acid sequence of human TNF, which has a potential for causing serious adverse effects, with asparagine residue and threoine residue, respectively, as well as a method of preparing the same utilizing recombinant DNA technology.
    Type: Grant
    Filed: November 20, 1987
    Date of Patent: August 14, 1990
    Assignee: Suntory Limited
    Inventors: Shoji Tanaka, Masafumi Tsujimoto, Yayoi Wada, Nobuo Tsuruoka, Hiroshi Nakazato